Base de dados : MEDLINE
Pesquisa : D27.505.954.483.508 [Categoria DeCS]
Referências encontradas : 2486 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 249 ir para página                         

  1 / 2486 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29419378
[Au] Autor:Chappell LC; Chambers J; Thornton JG; Williamson C
[Ad] Endereço:Women's Health Academic Centre, King's College London, London, UK lucy.chappell@kcl.ac.uk.
[Ti] Título:Does ursodeoxycholic acid improve perinatal outcomes in women with intrahepatic cholestasis of pregnancy?
[So] Source:BMJ;360:k104, 2018 02 01.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Colagogos e Coleréticos/efeitos adversos
Colestase Intra-Hepática/tratamento farmacológico
Feto/efeitos dos fármacos
Complicações na Gravidez/tratamento farmacológico
Ácido Ursodesoxicólico/efeitos adversos
[Mh] Termos MeSH secundário: Colagogos e Coleréticos/administração & dosagem
Colagogos e Coleréticos/uso terapêutico
Colestase Intra-Hepática/epidemiologia
Feminino
Seres Humanos
Gravidez
Complicações na Gravidez/epidemiologia
Resultado da Gravidez/epidemiologia
Ácido Ursodesoxicólico/administração & dosagem
Ácido Ursodesoxicólico/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholagogues and Choleretics); 724L30Y2QR (Ursodeoxycholic Acid)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180209
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.k104


  2 / 2486 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465536
[Au] Autor:Yan X; Jin J
[Ad] Endereço:Department of Hepatology, The First Hospital of Jilin University, Changchun, Jilin, China.
[Ti] Título:Primary cutaneous amyloidosis associated with autoimmune hepatitis-primary biliary cirrhosis overlap syndrome and Sjögren syndrome: A case report.
[So] Source:Medicine (Baltimore);97(8):e0004, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Primary cutaneous amyloidosis (PCA) is a localized skin disorder characterized by the abnormal deposition of amyloid in the extracellular matrix of the dermis. The association between PCA and other diseases, although rare, has been documented for various autoimmune diseases. PCA associated with autoimmune hepatitis-primary biliary cirrhosis (AIH-PBC) overlap syndrome and Sjögren syndrome (SS) has not been previously reported in the literature. PATIENT CONCERNS: A 50-year-old woman presented with progressive abnormal liver enzyme levels and was referred to our department. DIAGNOSES: Due to the patient's symptoms, laboratory test results, radiographic findings, and pathologic results, she was diagnosed with PCA associated with AIH-PBC overlap syndrome and SS. INTERVENTIONS: She was subsequently treated with a combination of ursodeoxycholic acid (UDCA), prednisone, and azathioprine. OUTCOMES: While this treatment can achieve therapeutic success, it cannot prevent complications from cirrhosis. This patient remains alive but experienced an emergent gastrointestinal hemorrhage. LESSONS: While we acknowledge that this is a single case, these findings extend our knowledge of immunological diseases associated with PCA and suggest a common, immune-mediated pathogenic pathway between PCA, AIH-PBC overlap syndrome, and SS. After 12 years of follow up, clinical manifestations have developed, and these autoimmune diseases have progressed. The combination of UDCA, prednisone, and azathioprine can achieve therapeutic success but cannot prevent disease progression. Routine follow up for this patient is necessary to document disease progression.
[Mh] Termos MeSH primário: Amiloidose Familiar/imunologia
Hepatite Autoimune/complicações
Cirrose Hepática Biliar/complicações
Síndrome de Sjogren/complicações
Dermatopatias Genéticas/imunologia
Doenças do Tecido Conjuntivo Indiferenciado/complicações
[Mh] Termos MeSH secundário: Amiloidose Familiar/tratamento farmacológico
Anti-Inflamatórios/administração & dosagem
Azatioprina/administração & dosagem
Colagogos e Coleréticos/administração & dosagem
Quimioterapia Combinada
Feminino
Hepatite Autoimune/tratamento farmacológico
Hepatite Autoimune/imunologia
Seres Humanos
Imunossupressores/administração & dosagem
Cirrose Hepática Biliar/tratamento farmacológico
Cirrose Hepática Biliar/imunologia
Meia-Idade
Prednisona/administração & dosagem
Síndrome de Sjogren/tratamento farmacológico
Síndrome de Sjogren/imunologia
Dermatopatias Genéticas/tratamento farmacológico
Resultado do Tratamento
Doenças do Tecido Conjuntivo Indiferenciado/tratamento farmacológico
Doenças do Tecido Conjuntivo Indiferenciado/imunologia
Ácido Ursodesoxicólico/administração & dosagem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Cholagogues and Choleretics); 0 (Immunosuppressive Agents); 724L30Y2QR (Ursodeoxycholic Acid); MRK240IY2L (Azathioprine); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000010004


  3 / 2486 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28836457
[Au] Autor:Silveira MG; Lindor KD
[Ad] Endereço:a Section of Digestive Diseases , Yale School of Medicine , New Haven , CT , USA.
[Ti] Título:Investigational drugs in phase II clinical trials for primary biliary cholangitis.
[So] Source:Expert Opin Investig Drugs;26(10):1115-1121, 2017 Oct.
[Is] ISSN:1744-7658
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease that may lead to biliary fibrosis, and eventually cirrhosis. The primary treatment for PBC is ursodeoxycholic acid (UDCA), which has favorably altered its natural history. However, up to 40% of patients have an inadequate response to UDCA, and are therefore at high risk of liver-related complications. Obeticholic acid has recently been approved for use in patients with PBC with inadequate response or who are intolerant to UDCA, but improvement in long-term outcomes has not yet been demonstrated. Alternative therapeutic options for PBC are needed. Areas covered: Recent advances in research including epidemiological, genetic and pre-clinical studies in animal models of PBC have yielded numerous agents currently at different stages of development for treatment of patients with PBC; in this review, we cover novel therapies that were recently or are recently being investigated in phase II clinical trials. Expert opinion: Despite the evolving landscape in PBC, the main challenges facing development of novel therapies remain the rarity of the disease and the limitations to design and conduct of controlled clinical trials in PBC, which are needed to determine the long-term effects of novel therapies on the clinical outcomes of PBC.
[Mh] Termos MeSH primário: Colangite/tratamento farmacológico
Desenho de Drogas
Drogas em Investigação/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Ácido Quenodesoxicólico/análogos & derivados
Ácido Quenodesoxicólico/uso terapêutico
Colagogos e Coleréticos/uso terapêutico
Colangite/complicações
Progressão da Doença
Seres Humanos
Cirrose Hepática Biliar/tratamento farmacológico
Ácido Ursodesoxicólico/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cholagogues and Choleretics); 0 (Drugs, Investigational); 0462Z4S4OZ (obeticholic acid); 0GEI24LG0J (Chenodeoxycholic Acid); 724L30Y2QR (Ursodeoxycholic Acid)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170825
[St] Status:MEDLINE
[do] DOI:10.1080/13543784.2017.1371135


  4 / 2486 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28425413
[Au] Autor:Melchor-Mendoza YK; Martínez-Benítez B; Mina-Hawat A; Rodríguez-Leal G; Duque X; Moran-Villota S
[Ad] Endereço:Social Service and Department of Pathology, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City.
[Ti] Título:Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability.
[So] Source:Ann Hepatol;16(3):430-435, 2017 May - Jun.
[Is] ISSN:1665-2681
[Cp] País de publicação:Mexico
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: There is little information on survival rates of patients with primary biliary cholangtis (PBC) in developing countries. This is particularly true in Latin America, where the number of liver transplants performed remains extremely low for patients with advanced liver disease who fulfill criteria for liver transplantation. The goal of this study was to compare survival rate of patients with PBC in developing countries who were treated with ursodeoxycholic acid (UDCA) versus survival of patients who received other treatments (OT) without UDCA, prescribed before the UDCA era. MATERIAL AND METHODS: A retrospective study was performed, including records of 78 patients with PBC in the liver unit in a third level referral hospital in Mexico City. Patients were followed for five years from initial diagnosis until death related to liver disease or to the end of the study. Patients received UDCA (15 mg/kg/per day) (n = 41) or OT (n = 37) before introduction of UDCA in Mexico. RESULTS: Response to treatment was higher in the group that received UDCA. In the five years of follow-up, survival rates were significantly higher in the UDCA group than in the OT group. The hazard ratio of death was higher in the OT group vs. UDCA group, HR 8.78 (95% CI, 2.52-30.61); Mayo Risk Score and gender were independently associated with the risk of death. CONCLUSIONS: The study confirms that the use of UDCA in countries with a limited liver transplant program increases survival in comparison to other treatments used before the introduction of UDCA.
[Mh] Termos MeSH primário: Colagogos e Coleréticos/uso terapêutico
Colangite/tratamento farmacológico
Acesso aos Serviços de Saúde
Cirrose Hepática Biliar/tratamento farmacológico
Transplante de Fígado
Doadores de Tecidos/provisão & distribuição
Ácido Ursodesoxicólico/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Colangite/diagnóstico
Colangite/mortalidade
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Cirrose Hepática Biliar/diagnóstico
Cirrose Hepática Biliar/mortalidade
Masculino
México
Meia-Idade
Modelos de Riscos Proporcionais
Estudos Retrospectivos
Fatores de Risco
Taxa de Sobrevida
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholagogues and Choleretics); 724L30Y2QR (Ursodeoxycholic Acid)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170421
[St] Status:MEDLINE
[do] DOI:10.5604/16652681.1235486


  5 / 2486 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28350426
[Au] Autor:Saffioti F; Gurusamy KS; Eusebi LH; Tsochatzis E; Davidson BR; Thorburn D
[Ad] Endereço:Sheila Sherlock Liver Centre, Royal Free Hospital and the UCL Institute of Liver and Digestive Health, Pond Street, Hampstead, London, UK, NW3 2QG.
[Ti] Título:Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis.
[So] Source:Cochrane Database Syst Rev;3:CD011648, 2017 03 28.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Primary biliary cholangitis (previously primary biliary cirrhosis) is a chronic liver disease caused by the destruction of small intra-hepatic bile ducts resulting in stasis of bile (cholestasis), liver fibrosis, and liver cirrhosis. The optimal pharmacological treatment of primary biliary cholangitis remains uncertain. OBJECTIVES: To assess the comparative benefits and harms of different pharmacological interventions in the treatment of primary biliary cholangitis through a network meta-analysis and to generate rankings of the available pharmacological interventions according to their safety and efficacy. However, it was not possible to assess whether the potential effect modifiers were similar across different comparisons. Therefore, we did not perform the network meta-analysis, and instead, assessed the comparative benefits and harms of different interventions using standard Cochrane methodology. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 2), MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical Trials Registry Platform, and randomised controlled trials registers to February 2017 to identify randomised clinical trials on pharmacological interventions for primary biliary cholangitis. SELECTION CRITERIA: We included only randomised clinical trials (irrespective of language, blinding, or publication status) in participants with primary biliary cholangitis. We excluded trials which included participants who had previously undergone liver transplantation. We considered any of the various pharmacological interventions compared with each other or with placebo or no intervention. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. We calculated the odds ratio (OR) and rate ratio with 95% confidence intervals (CI) using both fixed-effect and random-effects models based on available-participant analysis with Review Manager 5. We assessed risk of bias according to Cochrane, controlled risk of random errors with Trial Sequential Analysis, and assessed the quality of the evidence using GRADE. MAIN RESULTS: We identified 74 trials including 5902 participants that met the inclusion criteria of this review. A total of 46 trials (4274 participants) provided information for one or more outcomes. All the trials were at high risk of bias in one or more domains. Overall, all the evidence was low or very low quality. The proportion of participants with symptoms varied from 19.9% to 100% in the trials that reported this information. The proportion of participants who were antimitochondrial antibody (AMA) positive ranged from 80.8% to 100% in the trials that reported this information. It appeared that most trials included participants who had not received previous treatments or included participants regardless of the previous treatments received. The follow-up in the trials ranged from 1 to 96 months.The proportion of people with mortality (maximal follow-up) was higher in the methotrexate group versus the no intervention group (OR 8.83, 95% CI 1.01 to 76.96; 60 participants; 1 trial; low quality evidence). The proportion of people with mortality (maximal follow-up) was lower in the azathioprine group versus the no intervention group (OR 0.56, 95% CI 0.32 to 0.98; 224 participants; 2 trials; I = 0%; low quality evidence). However, it has to be noted that a large proportion of participants (25%) was excluded from the trial that contributed most participants to this analysis and the results were not reliable. There was no evidence of a difference in any of the remaining comparisons. The proportion of people with serious adverse events was higher in the D-penicillamine versus no intervention group (OR 28.77, 95% CI 1.57 to 526.67; 52 participants; 1 trial; low quality evidence). The proportion of people with serious adverse events was higher in the obeticholic acid plus ursodeoxycholic acid (UDCA) group versus the UDCA group (OR 3.58, 95% CI 1.02 to 12.51; 216 participants; 1 trial; low quality evidence). There was no evidence of a difference in any of the remaining comparisons for serious adverse events (proportion) or serious adverse events (number of events). None of the trials reported health-related quality of life at any time point. FUNDING: nine trials had no special funding or were funded by hospital or charities; 31 trials were funded by pharmaceutical companies; and 34 trials provided no information on source of funding. AUTHORS' CONCLUSIONS: Based on very low quality evidence, there is currently no evidence that any intervention is beneficial for primary biliary cholangitis. However, the follow-up periods in the trials were short and there is significant uncertainty in this issue. Further well-designed randomised clinical trials are necessary. Future randomised clinical trials ought to be adequately powered; performed in people who are generally seen in the clinic rather than in highly selected participants; employ blinding; avoid post-randomisation dropouts or planned cross-overs; should have sufficient follow-up period (e.g. five or 10 years or more); and use clinically important outcomes such as mortality, health-related quality of life, cirrhosis, decompensated cirrhosis, and liver transplantation. Alternatively, very large groups of participants should be randomised to facilitate shorter trial duration.
[Mh] Termos MeSH primário: Colangite/tratamento farmacológico
[Mh] Termos MeSH secundário: Azatioprina/efeitos adversos
Azatioprina/uso terapêutico
Ácido Quenodesoxicólico/efeitos adversos
Ácido Quenodesoxicólico/análogos & derivados
Ácido Quenodesoxicólico/uso terapêutico
Colagogos e Coleréticos/efeitos adversos
Colagogos e Coleréticos/uso terapêutico
Colangite/imunologia
Colangite/mortalidade
Doença Crônica
Colchicina/efeitos adversos
Colchicina/uso terapêutico
Ciclosporina/efeitos adversos
Ciclosporina/uso terapêutico
Seres Humanos
Imunossupressores/efeitos adversos
Imunossupressores/uso terapêutico
Metotrexato/efeitos adversos
Metotrexato/uso terapêutico
Mitocôndrias/imunologia
Metanálise em Rede
Penicilamina/efeitos adversos
Penicilamina/uso terapêutico
Qualidade de Vida
Ensaios Clínicos Controlados Aleatórios como Assunto
Ácido Ursodesoxicólico/efeitos adversos
Ácido Ursodesoxicólico/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Cholagogues and Choleretics); 0 (Immunosuppressive Agents); 0462Z4S4OZ (obeticholic acid); 0GEI24LG0J (Chenodeoxycholic Acid); 724L30Y2QR (Ursodeoxycholic Acid); 83HN0GTJ6D (Cyclosporine); GNN1DV99GX (Penicillamine); MRK240IY2L (Azathioprine); SML2Y3J35T (Colchicine); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170628
[Lr] Data última revisão:
170628
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170329
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD011648.pub2


  6 / 2486 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28291068
[Au] Autor:Grady B; Porphirio F; Rokhsar C
[Ad] Endereço:Dermatology, Hackensack University Medical Center - Palisades, North Bergen, New Jersey Dermatology, Escola de Medicina/BWS Consultoria Médica e Educacional LTDA, Fundação Técnico- Educacional Souza Marques, Rio de Janeiro, Brazil Dermatology, Mount Sinai School of Medicine, New York, New York.
[Ti] Título:Submental Alopecia at Deoxycholic Acid Injection Site.
[So] Source:Dermatol Surg;43(8):1105-1108, 2017 08.
[Is] ISSN:1524-4725
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Alopecia/induzido quimicamente
Queixo
Colagogos e Coleréticos/administração & dosagem
Técnicas Cosméticas
Ácido Desoxicólico/administração & dosagem
Pescoço
[Mh] Termos MeSH secundário: Tecido Adiposo/efeitos dos fármacos
Adulto
Seres Humanos
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholagogues and Choleretics); 005990WHZZ (Deoxycholic Acid)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170315
[St] Status:MEDLINE
[do] DOI:10.1097/DSS.0000000000001085


  7 / 2486 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28276816
[Au] Autor:Rodriguez EA; Carey EJ; Lindor KD
[Ad] Endereço:a Division of Gastroenterology and Hepatology , Mayo Clinic , Phoenix , AZ , USA.
[Ti] Título:Emerging treatments for primary sclerosing cholangitis.
[So] Source:Expert Rev Gastroenterol Hepatol;11(5):451-459, 2017 May.
[Is] ISSN:1747-4132
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Primary sclerosing cholangitis (PSC) is a chronic, cholestatic, idiopathic liver disease that can progress to end-stage liver disease, cirrhosis and cholangiocarcinoma. PSC is an uncommon and highly heterogeneous disease, associated with inflammatory bowel disease and a complex pathophysiology. To date, no medical therapies have proved effective. The only available treatment for end-stage PSC is liver transplant, but recurrence is a significant complication. Areas covered: This review will explore previously tested treatments, discuss current treatment strategies and present viewpoints about future emerging therapies in PSC. We searched PubMed using the noted keywords. We included data from full-text articles published in English. Further relevant articles were identified from the reference lists of review articles. Expert commentary: The development of new therapies in PSC has been challenging. However, with greater awareness of the disease nowadays, new insights into the disease may help in the design of future therapeutic agents in PSC and ultimately in effective therapies.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Colagogos e Coleréticos/uso terapêutico
Colangite Esclerosante/terapia
Endoscopia do Sistema Digestório
Transplante de Microbiota Fecal
Imunossupressores/uso terapêutico
[Mh] Termos MeSH secundário: Antibacterianos/efeitos adversos
Colagogos e Coleréticos/efeitos adversos
Colangite Esclerosante/diagnóstico
Colangite Esclerosante/imunologia
Colangite Esclerosante/microbiologia
Endoscopia do Sistema Digestório/efeitos adversos
Transplante de Microbiota Fecal/efeitos adversos
Seres Humanos
Imunossupressores/efeitos adversos
Transplante de Fígado/efeitos adversos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Cholagogues and Choleretics); 0 (Immunosuppressive Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170310
[St] Status:MEDLINE
[do] DOI:10.1080/17474124.2017.1293524


  8 / 2486 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28273237
[Au] Autor:de Oliveira Andrade R; Kunitake T; Koike MK; Machado MC; Souza HP
[Ad] Endereço:Faculdade de Medicina da Universidade de São Paulo, Departamento de Emergências Clínicas, São Paulo/SP, Brazil.
[Ti] Título:Effects of diazoxide in experimental acute necrotizing pancreatitis.
[So] Source:Clinics (Sao Paulo);72(2):125-129, 2017 Feb 01.
[Is] ISSN:1980-5322
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE:: We aimed to assess the effects of diazoxide on the mortality, pancreatic injury, and inflammatory response in an experimental model of acute pancreatitis. METHODS:: Male Wistar rats (200-400 g) were divided randomly into two groups. Fifteen minutes before surgery, animals received physiological (0.9%) saline (3 mL/kg) (control group) or 45 mg/kg diazoxide (treatment group) via the intravenous route. Acute pancreatitis was induced by injection of 2.5% sodium taurocholate via the biliopancreatic duct. Mortality (n=38) was observed for 72 h and analyzed by the Mantel-Cox Log-rank test. To study pancreatic lesions and systemic inflammation, rats (10 from each group) were killed 3 h after acute pancreatitis induction; ascites volume was measured and blood as well as pancreases were collected. Pancreatic injury was assessed according to Schmidt's scale. Cytokine expression in plasma was evaluated by the multiplex method. RESULTS:: Mortality at 72 h was 33% in the control group and 60% in the treatment group (p=0.07). Ascites volumes and plasma levels of cytokines between groups were similar. No difference was observed in edema or infiltration of inflammatory cells in pancreatic tissues from either group. However, necrosis of acinar cells was lower in the treatment group compared to the control group (3.5 vs. 3.75, p=0.015). CONCLUSIONS:: Treatment with diazoxide can reduce necrosis of acinar cells in an experimental model of acute pancreatitis, but does not affect the inflammatory response or mortality after 72 h.
[Mh] Termos MeSH primário: Diazóxido/farmacologia
Pancreatite Necrosante Aguda/tratamento farmacológico
Vasodilatadores/farmacologia
[Mh] Termos MeSH secundário: Animais
Colagogos e Coleréticos
Diazóxido/administração & dosagem
Modelos Animais de Doenças
Masculino
Pancreatite Necrosante Aguda/induzido quimicamente
Pancreatite Necrosante Aguda/mortalidade
Pancreatite Necrosante Aguda/patologia
Distribuição Aleatória
Ratos
Ratos Wistar
Ácido Taurocólico
Vasodilatadores/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholagogues and Choleretics); 0 (Vasodilator Agents); 5E090O0G3Z (Taurocholic Acid); O5CB12L4FN (Diazoxide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170309
[St] Status:MEDLINE


  9 / 2486 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28238692
[Au] Autor:Trivedi HD; Lizaola B; Tapper EB; Bonder A
[Ad] Endereço:Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.
[Ti] Título:Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review.
[So] Source:Am J Med;130(6):744.e1-744.e7, 2017 Jun.
[Is] ISSN:1555-7162
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Primary biliary cholangitis is an autoimmune condition characterized by destruction of intrahepatic bile ducts. It causes debilitating symptoms that dramatically affect the patient's quality of life. Pruritus affects 60% to 70% of individuals with primary biliary cholangitis and leads to sleep disturbances, fatigue, depression, and suicidal ideation. A complete search was performed with studies from PubMed, EMBASE, Web of Science, Cochrane database, Countway Library, and CINAHL with specific search terms. This narrative review was prepared after a comprehensive literature review. Treating patients with cholestatic pruritus is challenging and may have a profound impact on quality of life. The standard of therapy for primary biliary cholangitis, ursodeoxycholic acid, does not have a beneficial effect in cholestatic pruritus. Patients often do not respond to conventional therapies such as cholestyramine, rifampicin, opioid antagonists, and sertraline. These therapies lack long-term efficacy and have side effects. Patients who have not responded to these initial treatments can be considered for experimental therapies or clinical trials. This review outlines the current and emerging treatment modalities for patients with primary biliary cholangitis who have pruritus.
[Mh] Termos MeSH primário: Colangite/complicações
Prurido/terapia
[Mh] Termos MeSH secundário: Colagogos e Coleréticos/uso terapêutico
Colangite/tratamento farmacológico
Depressão/etiologia
Fadiga/etiologia
Seres Humanos
Prurido/complicações
Prurido/tratamento farmacológico
Prurido/etiologia
Qualidade de Vida
Transtornos do Sono-Vigília/etiologia
Ideação Suicida
Ácido Ursodesoxicólico/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cholagogues and Choleretics); 724L30Y2QR (Ursodeoxycholic Acid)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170822
[Lr] Data última revisão:
170822
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170228
[St] Status:MEDLINE


  10 / 2486 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28117681
[Au] Autor:Paridaens A; Raevens S; Devisscher L; Bogaerts E; Verhelst X; Hoorens A; Van Vlierberghe H; van Grunsven LA; Geerts A; Colle I
[Ad] Endereço:Department of Hepatology and Gastroenterology, Ghent University, 9000 Ghent, Belgium. Annelies.paridaens@ugent.be.
[Ti] Título:Modulation of the Unfolded Protein Response by Tauroursodeoxycholic Acid Counteracts Apoptotic Cell Death and Fibrosis in a Mouse Model for Secondary Biliary Liver Fibrosis.
[So] Source:Int J Mol Sci;18(1), 2017 Jan 20.
[Is] ISSN:1422-0067
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:The role of endoplasmic reticulum stress and the unfolded protein response (UPR) in cholestatic liver disease and fibrosis is not fully unraveled. Tauroursodeoxycholic acid (TUDCA), a hydrophilic bile acid, has been shown to reduce endoplasmic reticulum (ER) stress and counteract apoptosis in different pathologies. We aimed to investigate the therapeutic potential of TUDCA in experimental secondary biliary liver fibrosis in mice, induced by common bile duct ligation. The kinetics of the hepatic UPR and apoptosis during the development of biliary fibrosis was studied by measuring markers at six different timepoints post-surgery by qPCR and Western blot. Next, we investigated the therapeutic potential of TUDCA, 10 mg/kg/day in drinking water, on liver damage (AST/ALT levels) and fibrosis (Sirius red-staining), in both a preventive and therapeutic setting. Common bile duct ligation resulted in the increased protein expression of CCAAT/enhancer-binding protein homologous protein (CHOP) at all timepoints, along with upregulation of pro-apoptotic caspase 3 and 12, tumor necrosis factor receptor superfamily, member 1A (TNFRsf1a) and Fas-Associated protein with Death Domain (FADD) expression. Treatment with TUDCA led to a significant reduction of liver fibrosis, accompanied by a slight reduction of liver damage, decreased hepatic protein expression of CHOP and reduced gene and protein expression of pro-apoptotic markers. These data indicate that TUDCA exerts a beneficial effect on liver fibrosis in a model of cholestatic liver disease, and suggest that this effect might, at least in part, be attributed to decreased hepatic UPR signaling and apoptotic cell death.
[Mh] Termos MeSH primário: Apoptose/efeitos dos fármacos
Sistema Biliar/efeitos dos fármacos
Fígado/efeitos dos fármacos
Ácido Tauroquenodesoxicólico/farmacologia
Resposta a Proteínas não Dobradas/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Apoptose/genética
Sistema Biliar/metabolismo
Sistema Biliar/patologia
Doenças Biliares/etiologia
Doenças Biliares/genética
Doenças Biliares/prevenção & controle
Western Blotting
Caspase 12/genética
Caspase 12/metabolismo
Caspase 3/genética
Caspase 3/metabolismo
Colagogos e Coleréticos/farmacologia
Colestase/complicações
Modelos Animais de Doenças
Fibrose
Expressão Gênica/efeitos dos fármacos
Fígado/metabolismo
Fígado/patologia
Cirrose Hepática/etiologia
Cirrose Hepática/genética
Cirrose Hepática/prevenção & controle
Masculino
Camundongos
Reação em Cadeia da Polimerase Via Transcriptase Reversa
Fator de Transcrição CHOP/metabolismo
Fator de Necrose Tumoral alfa/genética
Resposta a Proteínas não Dobradas/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholagogues and Choleretics); 0 (Ddit3 protein, mouse); 0 (Tumor Necrosis Factor-alpha); 147336-12-7 (Transcription Factor CHOP); 516-35-8 (Taurochenodeoxycholic Acid); 60EUX8MN5X (tauroursodeoxycholic acid); EC 3.4.22.- (Caspase 12); EC 3.4.22.- (Caspase 3)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170424
[Lr] Data última revisão:
170424
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170125
[St] Status:MEDLINE



página 1 de 249 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde